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Abstract  
 
Attention Deficit/Hyperactivity Disorder (ADHD) like all common medical 
conditions is explained by the contribution of multiple genes and environmental 
risk factors. Family and twin studies consistently have observed a prominent 
genetic contribution but it is only recently that technological advances now have 
enabled direct genetic investigations. In this article I selectively review genetic 
findings on ADHD over the last five years and focus on their implications for the 
conceptualization of ADHD and future clinical practice.   
Recent, large-scale family studies and gene discoveries reveal the strong genetic 
overlaps between ADHD and Autism Spectrum Disorder, as well as Intellectual 
Disability. These findings highlight its neurodevelopmental nature.  ADHD 
however shows substantial genetic correlations with a much broader group of 
neuropsychiatric disorders, especially major depressive disorder as well as with 
non-psychiatric characteristics.  I discuss a few different explanations that might 
underlie these links.  ADHD while usefully conceptualized as a disorder in clinical 
practice, is commonly viewed as a continuously distributed trait in the fields of 
developmental psychopathology and epidemiology. Recent genome-wide 
association study findings consistent with previous twin studies, highlight that 
ADHD appears to lie at the extreme of a continuously distributed dimension akin 
to hypertension and blood pressure. New genetic findings on developmental 
continuity and change are discussed and I emphasize the need for a 
developmental perspective to genetic studies.  Finally, I consider potential future 
directions for scientists and the implications of new genetic findings for 
clinicians.  
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Introduction 
 
The concept of Attention Deficit Hyperactivity Disorder (ADHD) as a clinical 
condition can be traced back to well before the last century (1). The view that 
such behaviors arose from early “brain damage” remained highly influential 
through much of the 20th century until the first wave of family and twin 
studies(2) indirectly revealed the contribution of genetic risk factors. During the 
21st Century, technological advances and large-scale collaborative efforts have 
now enabled direct and successful genetic investigations into neuropsychiatric 
disorders,  including ADHD (3). 
ADHD, like all common medical conditions is not explained by genes alone; 
environmental risks also contribute (see elsewhere for a full discussion on 
environmental risk factors and designs to test causality (2)). In this article I 
selectively review genetic findings on ADHD over the last 5 years and focus on 
their implications for the conceptualization of ADHD and future clinical practice.   
 
Investigating the neurodevelopmental nature of ADHD  
Familial overlaps between ADHD and neurodevelopmental disorders: It has 
been known for decades that ADHD is familial and highly heritable (4) with 
heritability estimates of  around 60-90%. Twin studies also have shown a strong 
genetic overlap with other child psychopathology; most prominently with 
behavioral problems  such as conduct disorder (5). Indeed ADHD was considered 
primarily as an externalizing or behavioral problem (6). However more recent 
genetic studies have highlighted its neurodevelopmental nature (7). For 
example, national, registry-based family and twin studies have revealed a strong 
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familial and genetic overlap between ADHD and Autism Spectrum disorder 
(ASD).  In one Swedish study (8) the monozygotic co-twins of those with ASD 
showed an increased risk of ADHD (OR = 17.77 95% CI 9.8-32.22) compared to 
dizygotic co-twins (OR=4.33 95% CI 3.21-5.86). These associations were most 
prominent for those with higher functioning ASD rather than low functioning 
ASD (with intellectual disability). Although the within-individual and within-
family overlap of ADHD and ASD is now accepted, until the publication of DSM5, 
a diagnosis of ADHD in the presence of autism was disallowed. 
Recent genetic findings have also challenged the historical reticence about 
diagnosing ADHD in those with intellectual disability (ID) and about including 
those with lower IQ in genetic studies (9).  It has always been recognized that 
ADHD is strongly associated with lower IQ and intellectual disability (10). 
Population-based twin studies of IQ and learning ability (e.g. reading)  
consistently showed that most of the correlation with ADHD symptoms was 
explained by shared heritability (10). Interestingly, even though the genetic 
overlaps between ID and autism (11) and between ID and schizophrenia are well 
recognized (12), investigations into the genetic links between ID and ADHD have 
been sparse.  One recent registry-based, family study addressed this gap by 
examining ADHD diagnosis and intellectual disability (13). The authors found 
that most of the correlation between ADHD and ID liabilities was explained by 
genetic factors (estimate of 91%) except in the case of profound intellectual 
disability. Again these findings point to the neurodevelopmental nature of ADHD. 
These findings are important for scientists and clinicians. Historically, although 
those with lower IQ or ID have been excluded from studies of ADHD, this has not 
been the case for studies of schizophrenia or autism. This means that ADHD 
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research studies may not always have been fully representative of the clinic 
population.  
 
Rare genetic mutations of strong effect:  A number of rare Mendelian 
disorders and chromosomal anomalies are accompanied by ADHD as well as 
other neurodevelopmental and neuropsychiatric disorders. For example, ADHD 
is the most common neuropsychiatric disorder observed in 22q11.2 deletion 
syndrome (14) even though this syndrome is typically considered primarily as a 
psychosis risk factor.  ADHD is also associated with Tuberous Sclerosis, Smith-
Magenis Syndrome, Fragile X syndrome and Prader-Willi syndrome. These 
disorders however lead to a wide range of neurodevelopmental and 
neuropsychiatric phenotypes beyond ADHD, including ASD, anxiety, and 
depression and are often accompanied by intellectual disability and physical 
anomalies.   That is, none of these genetic syndromes are ADHD-specific. 
 
In the last decade, there have been growing efforts to identify novel, rare gene 
mutations that are associated with ADHD and other neuropsychiatric disorders 
through systematic investigations across the whole genome (3). One class of rare 
mutations, known as copy number variants (CNVs), that are chromosomal 
duplications and deletions, have been implicated in disorders that might be 
considered more neurodevelopmental in nature.  These include intellectual 
disability, autism, schizophrenia and more recently Tourette’s syndrome as well 
as ADHD (3,15).  The genomic regions spanned by the ADHD-associated CNVs 
have been found to show significant overlap with CNVs involved in autism and 
schizophrenia highlighting the highly pleiotropic effect of CNVs. 
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The largest and only systematic investigation of  another class of rare mutations 
in ADHD, rare exome sequence variants, comes from an as yet unpublished study 
of  3536 individuals with ADHD from the Danish iPSYCH register-based study 
(16). The investigators observed a similar burden of rare protein truncating 
variants (PTVs) in ADHD as was found in ASD and both neurodevelopmental 
groups were enriched for PTVs above the unaffected control rate (OR=1.24 for 
ADHD vs 0R= 1.23 for ASD). Intriguingly, the authors found that the genes 
affected by ADHD and ASD rare variants were indistinguishable.  
  
Common gene variants of small effect size shared between ADHD and 
different neurodevelopmental disorders and traits:  Very large sample sizes 
are required to detect individual common gene variants using genome-wide 
association study (GWAS) designs and until recently, these have been lacking for 
ADHD. However, the most recent ADHD GWAS included  20, 183 ADHD cases and 
35, 191 controls and robustly implicated 12 independent genomic loci (18), 
including one containing the gene FOXP2 that has previously been implicated in 
severe speech and language(17) problems. As none of the genome-wide 
significant loci contained any of the candidate genes previously implicated in 
ADHD (e.g. dopaminergic genes), this earlier literature is not discussed further.  
It is possible that evidence implicating some of these genes could emerge with 
larger GWAS.  
 
Males are more commonly affected by ADHD and this is a characteristic feature 
of child neurodevelopmental disorders. Although previous studies based on 
siblings had suggested that females with ADHD may carry a higher burden of 
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ADHD genetic risk, and this would be a potential explanation for why males are 
more commonly affected (because females have to carry a greater burden of risk 
to manifest disorder), the latest GWAS findings did not show this (19). 
 
Puzzlingly and in contrast to family and twin study findings, the international 
Psychiatric Genomics Consortium (PGC) cross-disorder study published in 2013 
(20) found no genetic overlap between ADHD and ASD. In contrast, the more 
recent and much larger Danish nationwide iPSYCH GWAS of ASD observed a 
significant genetic correlation of 0.360 between ADHD and ASD (21). One 
possible explanation is that the 2013 PGC ASD sample was trio based (both 
parents and offspring) and might have included ascertainment biases, while the 
Danish sample was a nation-wide design based on all affected individuals (case-
control). More importantly the new iPSYCH GWAS is very much larger and thus 
better powered. 
 
 From the perspective of recent genetic discoveries, ADHD behaves as a typical 
neurodevelopmental disorder with a higher burden of rare mutations compared 
to controls and with genetic overlap with ASD and ID. However as we will 
discuss next, genetic overlap is extensive amongst different neuropsychiatric 
disorders, and the genetic links of ADHD are not restricted to a 
neurodevelopmental grouping.  
 
Genetic overlap between ADHD and other neuropsychiatric disorders  
One of the most striking findings to emerge from GWAS is the extensive genetic 
overlap for biomedical traits and disorders (22). ADHD GWAS findings are no 
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exception; ADHD showed significant  positive genetic correlation with a wide 
range of neuropsychiatric disorders including schizophrenia, bipolar disorder, 
Tourette’s syndrome, anxiety disorder and major depressive disorder and a 
significant negative genetic correlation with anorexia nervosa (18). ADHD also 
shows genetic overlap with some physical conditions (e.g. lung cancer, insomnia, 
migraine) as well as some social and environmental phenotypes (e.g. educational 
attainment, smoking behaviors)(18).  It is clear therefore that ADHD does not 
show genetic overlap with neurodevelopmental disorders alone and that risk 
factors (e.g. gene or gene group or environmental risk such as smoking) for 
complex disorders including ADHD, do not necessarily provide a good means of 
defining diagnostic boundaries or meaningful groupings or making treatment 
decisions. 
 
These recent GWAS findings of pleiotropy are not enormously surprising given 
that recent family and twin studies had also observed familial and genetic 
overlaps between ADHD and later-onset neuropsychiatric problems including 
schizophrenia, bipolar disorder(23),  major depressive disorder (MDD) (24), as 
well as deliberate self-harm(25), completed suicide (25) and alcohol misuse(26).  
The observation of genetic overlap in itself is no longer a novel or clinically 
useful observation. Rather, we should be asking: what are the reasons that 
underlie these genetic correlations? For example, GWAS findings reveal that 
ADHD, typically an early-onset disorder, shows the strongest genetic correlation 
with major depressive disorder (rg=0.42).  Is that because ADHD has an 
especially close biological relationship with depression? There is limited 
evidence to date to support this hypothesis. Does pleiotropy represent a causal 
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risk effect of ADHD on MDD? Consistent with this providing a partial explanation, 
some studies suggest that treatment of ADHD reduces the risk of  future 
depression (27).  However ADHD treatments are not effective for MDD. Another 
hypothesis is that a substantial proportion of those with recurrent MDD who are 
recruited into GWAS are misclassified and have undiagnosed ADHD or a history 
of ADHD but this seems unlikely to be a full explanation. These are all hypotheses 
that can be tested via  epidemiological designs and novel genomic methods (e.g. 
Mendelian Randomization) to disaggregate pleiotropy among other designs (28).   
 
 
Conceptualizing ADHD as a trait and category 
 
From an epidemiological perspective, ADHD can be viewed as a trait as well as a 
category; higher scores are associated with adverse outcomes with no 
discontinuity at a specific cut-point(7). Although a diagnostic category for ADHD 
is helpful in clinical practice because many clinical decisions are categorical in 
nature (e.g. to use medication versus not), an understanding of its underlying 
structure can be informative for clinicians and patients as well as researchers.  
Twin studies suggested many years ago that ADHD appears to lie at the end of a 
continuum of genetic risk, with the same genetic risks contributing across the 
ADHD continuum in the population(2) with the possible exception of those 
scoring at the very low extreme end of the continuum(29). These findings, 
coupled with epidemiological studies, suggested that ADHD could be viewed as 
something akin to hypertension where the disorder lies at the extreme of a 
continuously distributed phenotype (i.e. blood pressure) that is present in the 
whole population.  
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GWAS findings have further added to this evidence.  Two studies used an 
independent ADHD GWAS discovery dataset  to generate ADHD polygenic risk 
scores (PRS),  the relative burden of ADHD risk alleles carried by an individual, in 
population cohorts in the UK (30) and the Netherlands(31). Both found that 
ADHD PRS predicted ADHD trait levels in the general population. A third UK 
study(32) further observed that when PRS were derived for an ADHD trait 
measure in a population-based cohort, these predicted ADHD diagnosis in an 
independent patient sample.  The most recent and largest ADHD GWAS (18) was 
able to go further by testing the genetic correlation between ADHD diagnosis and 
a large GWAS meta-analysis of ADHD trait measures in 17,666 European 
individuals from the EAGLE consortium(33). The findings are striking in that the 
investigators observe a genetic correlation of 0.94 between ADHD diagnosis in 
patients and ADHD traits in the population-based cohorts. Overall genetic 
findings converge in showing that ADHD diagnosis lies at the extreme of a 
quantitative trait.  
However ADHD diagnosis genetic risk is not exclusively related to a single 
continuously distributed trait measure of ADHD. For example, one population-
based cohort study(34) found that ADHD genetic risk scores predicted multiple 
childhood neurodevelopmental traits including social communication, cognitive 
ability/IQ, language and working memory although not emotion recognition. The 
findings on working memory recently have been replicated (35).  Another study 
found ADHD genetic risk scores also predicted childhood irritability (36).  These 
findings could simply reflect pleiotropy once again; with the same genes 
contributing to different childhood traits in the population. An alternative 
interpretation for the clinician and scientist is that a diagnosis of ADHD could be 
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conceptualized as the extreme of multiple liabilities or dimensions; this would be 
in keeping with the thinking of R-DoC.  
 
Development and adult life 
Although ADHD symptom levels typically decline with age, a proportion of 
individuals show persistently elevated symptoms or a continued diagnosis into 
adolescence or adult life(7). Longitudinal twin studies have all observed that 
ADHD persistence is associated with higher genetic loading; one study further 
suggested that ADHD trajectories through adolescence maybe explained by 
genetic liabilities that are independent of those that contribute to  baseline 
symptom levels in childhood (37). A recent population-based, cohort 
investigation used ADHD GWAS findings to assess the contribution of ADHD 
common genetic variants to ADHD symptom trajectories between ages 4 and 17 
years(38). ADHD PRS were significantly higher in children in the persistent 
trajectory than in those in a low symptom group (OR 1.31), an intermediate 
group (OR=1.22) and in a childhood-limited ADHD group (OR 1.27). Interestingly 
although the schizophrenia GWAS discovery sample is very much larger and 
more powerful than the ADHD GWAS, schizophrenia PRS and other 
neuropsychiatric PRS did not predict ADHD persistence. This highlights that 
there is a degree of specificity to genetic findings. 
 
Other genetic studies that have assessed adult ADHD in individuals over the age 
of 18 years using cross-sectional designs also support the suggestion that 
persistent ADHD has higher genetic loading. For example, a recent family-
Swedish registry-based family study observed a substantially higher relative risk 
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of clinically recognized ADHD in siblings of those who had ADHD at age 18 or 
older (Hazard Ratio HR 11.49) than siblings of those with ADHD at a younger 
age-below the age of 18 years (HR  4.68)(39).  
However twin studies of adult ADHD repeatedly have yielded very low 
heritability estimates, in contrast to the consistently high heritability estimates 
observed in child twin studies. A Swedish registry study (40) however showed 
substantial heritability for ADHD across the life span including in adult life 
(h2=0.72 95% CI 0.56-.84). Here, ADHD was defined using an ICD diagnosis or on 
the basis of prescribed ADHD medication. These findings suggest that with a 
clinician’s diagnosis, where perhaps age of onset, symptom pervasiveness and 
impairment criteria are used rather than self-report questionnaire measures, the 
developmental differences in genetic architecture are not as pronounced at least 
in terms of twin study findings.  
 
Although there are international efforts to assemble large adult ADHD datasets, 
so far GWAS have yet to yield genome-wide significant loci and rare variant 
studies(41,42) will also require much larger sample sizes before they can be 
used to further assess developmental differences in ADHD genetic architecture at 
a molecular level  (see Franke et al(43) for an extensive review of adult ADHD 
genetics). 
 
 
 
 
Future directions 
 
The 21st century has witnessed the discovery of ADHD-associated rare and 
common genetic variants and resolved that its genetic architecture involves a 
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spectrum of genetic variation in terms of frequencies and effect sizes.  These 
discoveries are already providing a start-point to gaining insights into the 
underlying biology of ADHD (e.g.(44,45) and for assessing novel treatments 
(46)). However, much more work will be needed to investigate the functional 
impacts of associated genetic variants at the level of molecules, cells, neural 
systems and circuits, as well as on development. Another observation is that so 
far, the identified genetic variants only explain a relatively small fraction of the 
inferred heritability (h2=-0.22)(18) of ADHD that has been inferred from 
traditional genetic designs. This suggests that continued collaborative and larger 
ADHD genetic discovery studies will be required in the future to detect 
additional genetic contributions together with robust epidemiological designs to 
identify causal environmental risk factors. Novel strategies may be needed to 
consider alternative plausible risk mechanisms that might manifest as 
heritability, for example parentally-provided early environments(47) including 
the prenatal environment. The literature review of the previous five years on 
ADHD genetics has shown the enormous advantage of genetically-informative 
and genotyped nationwide patient registries and these will continue to remain 
an invaluable resource for investigating many of the questions raised in this 
review.  
   
Recent genetic discoveries highlight the strong overlap between ADHD, ASD and 
ID.  Indeed, in terms of rare mutations ADHD and ASD seem virtually 
identical(16), so it is welcome that previous diagnostic exclusion criteria for 
ADHD in the presence of ASD have been removed from DSM-5. Yet the clinical 
features and treatments of these disorders are so different. What determines 
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these differences is another crucial next research question (Figure 1).  Typically 
these are early onset disorders. One possible contribution to differences is 
variation in prenatal environmental exposures, another is background common 
genetic variants. For example, ADHD common genetic variant risk scores predict 
lower cognitive ability and educational attainment, whereas ASD common 
genetic variants predict higher cognition and attainment (48). Lessons from 
genetic discoveries on strong diagnostic overlaps are timely for clinicians and 
especially for service providers that tend to be diagnosis-specific (e.g. ASD only) 
especially given the historical reticence about diagnosing ADHD in the context of 
ASD or ID. This is beginning to be recognized. For example, in 2017 in Wales, a 
nation of 3 million, multi-disciplinary child neurodevelopmental clinics informed 
by recent findings have been established recently and have replaced ASD and 
ADHD-specific assessment pathways. 
  
In the last five years, GWAS have shown genetic overlap across multiple 
disorders. ADHD shows extensive pleiotropy that is especially prominent with 
major depressive disorder but genetic risks also show some specificity as only 
ADHD PRS appear to predict ADHD persistence(38). In the next five years, efforts 
need to focus on disaggregating this pleiotropy and testing alternative 
hypotheses using methods that are able to distinguish causal relationships, 
different ADHD subtypes and misclassification from pleiotropy (e.g. using 
Mendelian randomization and other similar methods). This is important because 
the different explanations will have diverse clinical implications (Figure 1).  
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Genetic findings have confirmed the epidemiological view of ADHD as lying at 
the extreme of a continuum (or several continua) and have started to highlight 
the importance of adopting a developmental perspective(37,38). Funders and 
ethics bodies need to recognize that developmental studies require longitudinal 
follow up and that this is expensive and time consuming yet scientifically 
invaluable. In this regard, longitudinal, population cohort designs are attractive 
for developmentally-informative genetic studies because, unlike patient registry 
data, they involve trait-based assessments; however non-random attrition is a 
problem and those with severe illness (at the extremes of dimensions) are 
under-represented. If ADHD is a trait, akin to blood pressure, then public 
/population health-based samples and approaches can be integrated with 
traditional genetics research on patients. This is beginning to happen.  The 
conceptualization of ADHD as both a trait and a disorder is relevant to clinicians 
in that most will recognize the somewhat arbitrary nature of the diagnostic cut-
point and frequently encounter sub-threshold cases. The presence of an 
underlying continuum means issues such as defining the boundary for 
impairment and treatment are not straightforward.  For example, the blood 
pressure cut-point for defining hypertension has changed over time, and 
hypertension guidelines in some countries adjust the cut-point depending on 
comorbid disease (e.g. chronic renal disease).    
 
Given recent genetic discoveries, what are the implications for genetic testing in 
ADHD?  The implication for clinicians are two-fold. First, relatives of those with 
ADHD including their parents are at elevated risk of a range of different 
neurodevelopmental disorders (e.g. ADHD, ASD, learning difficulties) as well as 
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other neuropsychiatric illnesses (most commonly MDD) that could impact on 
assessment, treatment delivery or treatment effectiveness. At present, routine 
testing for rare mutations in ADHD is not recommended although guidelines for 
such testing in clinical settings have now expanded in many countries to include 
mild intellectual disability as well as ASD in the US. It was not long ago that mild 
intellectual disability was considered primarily socio-cultural in origin so this 
represents a substantial shift in international clinical practice. There is little 
empirical evidence to guide us as to what should happen for ADHD. A much older 
study showed that the rate of established syndromes was sufficiently rare in 
ADHD that genetic testing is not warranted in those without ID (49). However 
that study predates current methods for detecting genomic anomalies and a 
crucial issue is how severely neurodevelopmentally impaired the target patient 
group is, especially given that ADHD is relatively common. Whether genetic 
testing in clinical settings extends to neuropsychiatric disorders such as ADHD 
and schizophrenia remains to be seen but as costs diminish and more knowledge 
about the causality of different mutations is gained, in my view clinical practice is 
likely to change within the next decade. This could be sooner if some of these 
rare mutations are found to have treatment or prognostic implications or are 
medically actionable. 
The clinical utility of common genetic risk variants is less certain because their 
predictive power is weak and risk effects are defined in relation to a population 
rather than an individual. It is possible in the future that combining information 
on common genetic risk scores and family history (50)could be helpful for 
stratifying patients for the purpose of treatment or prognosis; for example in 
identifying those who are at elevated risk of future psychosis or in guiding 
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treatment.  At present however these remain the domain of research questions 
that need to be answered. 
 
In summary, many novel genetic findings on ADHD have emerged and will 
continue to do so in the 21st century. Such discoveries are of interest and 
relevance in my view to a much broader scientific field including neuroscientists, 
developmental scientists and population epidemiologists, as well as clinicians 
because they contribute to our conceptualization of ADHD and can shape the 
next five years of research and clinical practice.   
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Figure 1 
ADHD shows neurodevelopmental overlaps and pleiotropy: questions for 
the future 
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